ClinicalTrials.gg
CompletedNCT05691712SURPASS-CN-INSUpdated Aug 8, 2025Results posted

A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

A Phase 3 interventional study of Tirzepatide and Placebo in Diabetes Type 2, Diabetes Mellitus and Glucose Metabolism Disorders, sponsored by Eli Lilly and Company. Completed at 25 sites in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-08.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
257
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.

Enrollment
18th of 43
257 · median 160
Started
2023
with 5 others
Phase 3
17 of 43
1 open now
Registered
25th of 43
by date
Lead sponsor
31 of 43
Eli Lilly and Company

Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 18th largest by enrollment, is one of 6 that started in 2023, is one of 17 in phase 3, and was the 25th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to compare the effect of the addition of tirzepatide or placebo to titrated basal insulin on glycemic control in Chinese participants with type 2 diabetes.

03

Conditions studied

  • Diabetes Type 2
  • Diabetes Mellitus
  • Glucose Metabolism Disorders
  • Metabolic Disease
  • Endocrine System Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have type 2 diabetes mellitus (T2DM)
  • Have ≥7.0% (53 mmol/mol) to ≤11% (97 mmol/mol)
  • Have been treated with insulin glargine (U100) once daily alone, or in combination with metformin with or without SGLT-2i ≥90 days
  • Have a (BMI) ≥23 kilograms per meter squared (kg/m²)

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes mellitus (T1DM)
  • Have a history of chronic or acute pancreatitis
  • Have proliferative diabetic retinopathy or diabetic macular edema or nonproliferative diabetic retinopathy that requires acute treatment
  • Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2
  • Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months
  • Have a history of diabetic ketoacidosis or hyperosmolar state/coma within the 6 months
  • Have acute myocardial infarction, or cerebrovascular accident (stroke) or hospitalization due to congestive heart failure (CHF) in the past 2 months
  • Have a serum calcitonin level of ≥35 ng/L, as determined by central laboratory
  • Have acute or chronic hepatitis, signs, and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD), or (ALT) level >3.0 times the (ULN), as determined by the central laboratory at study entry; participants with NAFLD are eligible for participation in this trial only if their ALT level is ≤3.0 times ULN.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
257 participants (actual)

Study arms

  • Experimental
    5 Milligram (mg) Tirzepatide

    Participants received 5 mg of tirzepatide administered as subcutaneous (SC) injection via a single-dose injection pen (SDP) once weekly (QW) for 40 weeks. The starting dose of tirzepatide was 2.5 mg QW, which increased by 2.5 mg every 4 weeks until the maintenance dose of 5 mg was reached.

    Drug: Tirzepatide

  • Experimental
    10 mg Tirzepatide

    Participants received 10 mg of tirzepatide administered as SC injection via a SDP QW for 40 weeks. The starting dose of tirzepatide was 2.5 mg QW, which increased by 2.5 mg every 4 weeks (2.5 mg to 5 mg to 7.5 mg to 10 mg) until the maintenance dose of 10 mg was reached.

    Drug: Tirzepatide

  • Experimental
    15 mg Tirzepatide

    Participants received 15 mg of tirzepatide administered as SC injection via a SDP QW for 40 weeks. The starting dose of tirzepatide was 2.5 mg QW, which increased by 2.5 mg every 4 weeks (2.5 mg to 5 mg to 7.5 mg to 10 mg to 12.5 mg to 15 mg) until the maintenance dose of 15 mg was reached.

    Drug: Tirzepatide

  • Placebo comparator
    Placebo

    Participants received tirzepatide matched placebo administered as SC injection via a SDP QW for 40 weeks.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3298176

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in HbA1c (Tirzepatide 10 or 15 Milligram [mg])

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least squares (LS) mean was calculated using mixed model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + SGLT2i Use (Yes/No) + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured

    Time frame: Baseline, Week 40

Secondary outcomes

  1. Mean Change From Baseline in HbA1c (Tirzepatide 5 mg)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was calculated using MMRM for post-baseline measures: Variable = Baseline + SGLT2i Use (Yes/No) + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured

    Time frame: Baseline, Week 40

  2. Mean Change From Baseline in Body Weight

    LSMean was calculated using MMRM for post-baseline measures: Variable = Baseline + Baseline HbA1c (\<=8.0%, \>8.0%) + SGLT2i Use (Yes/No) + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured

    Time frame: Baseline, Week 40

  3. Percentage of Participants With HbA1c <7.0% (53 Millimole/Mole [mmol/Mol]) and ≤6.5% (48 mmol/Mol)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Percentage of Participants with HbA1c \<7.0% (53 millimole/mole \[mmol/mol\]) and ≤6.5% (48 mmol/mol) is reported here.

    Time frame: Week 40

  4. Mean Change From Baseline in Fasting Serum Glucose

    LSMean was calculated using MMRM for post-baseline measures: Variable = Baseline + Baseline HbA1c (\<=8.0%, \>8.0%) + SGLT2i Use (Yes/No) + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured

    Time frame: Baseline, Week 40

  5. Percentage of Participants With HbA1c <5.7% (39 mmol/Mol) [Tirzepatide 10 mg or 15 mg]

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Percentage of participants with HbA1c \<5.7% (39 mmol/Mol) is reported here.

    Time frame: Week 40

  6. Percentage of Participants With HbA1c <5.7% (39 mmol/Mol) [Tirzepatide 5 mg]

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Percentage of participants with HbA1c \<5.7% (39 mmol/Mol) is reported here.

    Time frame: Week 40

  7. Mean Change From Baseline in Daily Average 7-point Self-monitored Blood Glucose Profiles

    The SMBG data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Post meal, Midday Premeal, Midday 2-hour Post meal, Evening Premeal, Evening 2-hour Post meal and Bedtime. The daily average was calculated as the average of the 7 blood glucose values collected on a particular day. LS Mean was calculated using MMRM for post-baseline measures: Variable = Baseline + Baseline HbA1c (\<=8.0%, \>8.0%) + SGLT2i Use (Yes/No) + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 40

  8. Percentage of Participants Who Achieved Weight Loss of ≥5%

    Percentage of Participants who Achieved Weight Loss ≥5% is reported here.

    Time frame: Week 40

  9. Percentage of Participants Who Achieved Weight Loss of ≥10%

    Percentage of Participants who Achieved Weight Loss ≥10% is reported here.

    Time frame: Week 40

  10. Percentage of Participants Who Achieved Weight Loss of ≥15%

    Percentage of Participants who Achieved Weight Loss ≥15% is reported here.

    Time frame: Week 40

  11. Percent Change From Baseline in Daily Mean Insulin Glargine Dose

    LS Mean was calculated using MMRM for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Baseline HbA1c (\<=8.0%, \>8.0%) + SGLT2i Use (Yes/No) + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 40

  12. Percentage of Participants With HbA1c <7.0%, Without Weight Gain (<0.1 Kilogram [kg]) and Without Hypoglycemia, (Blood Glucose <3.0 mmol/L <54 Milligram/Deciliter [mg/dL])

    Percentage of Participants with HbA1c \<7.0%, Without Weight Gain (\<0.1 Kilogram \[kg\]) and Without Hypoglycemia, (Blood Glucose \<3.0 mmol/L \<54 Milligram/Deciliter \[mg/dL\]) is reported here

    Time frame: Week 40

  13. Percentage of Participants With HbA1c ≤6.5%, Without Weight Gain <0.1 kg and Without Hypoglycemia (Blood Glucose <3.0 mmol/L [54 mg/dL])

    Percentage of Participants with HbA1c ≤6.5%, Without Weight Gain \<0.1 kg and Without Hypoglycemia (Blood glucose \<3.0 mmol/L \[54 mg/dL\]) is reported here.

    Time frame: Week 40

  14. Percentage of Participants With HbA1c <7.0%, Without Weight Gain <0.1 kg and Without Hypoglycemia (Blood Glucose <3.9 mmol/L [70 mg/dL] or Severe Hypoglycemia)

    Percentage of Participants with HbA1c \<7.0%, Without Weight Gain \<0.1 kg and Without Hypoglycemia (Blood Glucose \<3.9 mmol/L \[70 mg/dL\] or Severe Hypoglycemia) is reported here.

    Time frame: Week 40

  15. Percentage of Participants With HbA1c ≤6.5%, Without Weight Gain <0.1 kg and Without Hypoglycemia (Blood Glucose <3.9 mmol/L [70 mg/dL] or Severe Hypoglycemia)

    Percentage of Participants with HbA1c ≤6.5%, Without Weight Gain \<0.1 kg and Without Hypoglycemia (Blood glucose \<3.9 mmol/L \[70 mg/dL\] or Severe Hypoglycemia) is reported here.

    Time frame: Week 40

07

Results

Posted Aug 8, 2025

Participant flow

Participant flow — Overall Study
Milestone5 Milligram (mg) Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Started65656364
Received at least one dose of study drug65656364
Completed61605861
Not completed4553
Withdrew: Adverse event0121
Withdrew: Withdrawal by subject2331
Withdrew: Death1000
Withdrew: Pregnancy0100
Withdrew: Assigned treatment by mistake1001

Outcome measures

PrimaryMean Change From Baseline in HbA1c (Tirzepatide 10 or 15 Milligram [mg])

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least squares (LS) mean was calculated using mixed model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + SGLT2i Use (Yes/No) + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · millimoles per mole (mmol/mol)
Mean Change From Baseline in HbA1c (Tirzepatide 10 or 15 Milligram [mg])
millimoles per mole (mmol/mol)10 mg Tirzepatide15 mg TirzepatidePlacebo
Mean Change From Baseline in HbA1c (Tirzepatide 10 or 15 Milligram [mg])-26.1 ± 1.367-25.9 ± 1.386-9.96 ± 1.340
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -16.1 · 95% CI -19.9 to -12.36
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -15.9 · 95% CI -19.7 to -12.10
SecondaryMean Change From Baseline in HbA1c (Tirzepatide 5 mg)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was calculated using MMRM for post-baseline measures: Variable = Baseline + SGLT2i Use (Yes/No) + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · mmol/mol
Mean Change From Baseline in HbA1c (Tirzepatide 5 mg)
mmol/mol5 mg TirzepatidePlacebo
Mean Change From Baseline in HbA1c (Tirzepatide 5 mg)-23.0 ± 1.329-9.96 ± 1.340
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -13.06 · 95% CI -16.8 to -9.34
SecondaryMean Change From Baseline in Body Weight

LSMean was calculated using MMRM for post-baseline measures: Variable = Baseline + Baseline HbA1c (\<=8.0%, \>8.0%) + SGLT2i Use (Yes/No) + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · kilograms (kg)
Mean Change From Baseline in Body Weight
kilograms (kg)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Mean Change From Baseline in Body Weight-2.7 ± 0.52-4.8 ± 0.54-4.3 ± 0.551.7 ± 0.53
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -4.4 · 95% CI -5.8 to -2.9
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -6.5 · 95% CI -8.0 to -5.0
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -6.0 · 95% CI -7.5 to -4.5
SecondaryPercentage of Participants With HbA1c <7.0% (53 Millimole/Mole [mmol/Mol]) and ≤6.5% (48 mmol/Mol)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Percentage of Participants with HbA1c \<7.0% (53 millimole/mole \[mmol/mol\]) and ≤6.5% (48 mmol/mol) is reported here.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c <7.0% (53 Millimole/Mole [mmol/Mol]) and ≤6.5% (48 mmol/Mol)
percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
HbA1c <7.0%75.8178.9578.1817.24
HbA1c ≤6.5%59.6877.1969.096.90
SecondaryMean Change From Baseline in Fasting Serum Glucose

LSMean was calculated using MMRM for post-baseline measures: Variable = Baseline + Baseline HbA1c (\<=8.0%, \>8.0%) + SGLT2i Use (Yes/No) + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · milligram per deciliter (mg/dL)
Mean Change From Baseline in Fasting Serum Glucose
milligram per deciliter (mg/dL)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Mean Change From Baseline in Fasting Serum Glucose-45.5 ± 3.73-52.5 ± 3.87-51.0 ± 3.94-23.7 ± 3.84
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -21.9 · 95% CI -32.4 to -11.3
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -28.9 · 95% CI -39.6 to -18.1
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -27.3 · 95% CI -38.2 to -16.5
SecondaryPercentage of Participants With HbA1c <5.7% (39 mmol/Mol) [Tirzepatide 10 mg or 15 mg]

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Percentage of participants with HbA1c \<5.7% (39 mmol/Mol) is reported here.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c <5.7% (39 mmol/Mol) [Tirzepatide 10 mg or 15 mg]
percentage of participants10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants With HbA1c <5.7% (39 mmol/Mol) [Tirzepatide 10 mg or 15 mg]17.5425.450.00
SecondaryPercentage of Participants With HbA1c <5.7% (39 mmol/Mol) [Tirzepatide 5 mg]

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Percentage of participants with HbA1c \<5.7% (39 mmol/Mol) is reported here.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c <5.7% (39 mmol/Mol) [Tirzepatide 5 mg]
percentage of participants5 mg TirzepatidePlacebo
Percentage of Participants With HbA1c <5.7% (39 mmol/Mol) [Tirzepatide 5 mg]9.680.00
SecondaryMean Change From Baseline in Daily Average 7-point Self-monitored Blood Glucose Profiles

The SMBG data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Post meal, Midday Premeal, Midday 2-hour Post meal, Evening Premeal, Evening 2-hour Post meal and Bedtime. The daily average was calculated as the average of the 7 blood glucose values collected on a particular day. LS Mean was calculated using MMRM for post-baseline measures: Variable = Baseline + Baseline HbA1c (\<=8.0%, \>8.0%) + SGLT2i Use (Yes/No) + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · millimoles per liter per day(mmol/L/day)
Mean Change From Baseline in Daily Average 7-point Self-monitored Blood Glucose Profiles
millimoles per liter per day(mmol/L/day)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Morning Premeal - Fasting-2.62 ± 0.127-2.53 ± 0.132-2.80 ± 0.136-2.22 ± 0.131
Morning 2-hour Postmeal-4.78 ± 0.300-5.34 ± 0.306-5.05 ± 0.313-2.57 ± 0.300
Midday Premeal-2.87 ± 0.247-3.52 ± 0.258-3.26 ± 0.263-1.32 ± 0.253
Midday 2-hour Postmeal-4.05 ± 0.318-4.10 ± 0.325-3.65 ± 0.335-1.46 ± 0.322
Evening Premeal-2.84 ± 0.264-3.64 ± 0.276-3.20 ± 0.285-0.95 ± 0.271
Evening 2-hour Postmeal-3.97 ± 0.347-4.52 ± 0.351-4.42 ± 0.367-1.47 ± 0.346
Bedtime-3.41 ± 0.287-4.19 ± 0.297-3.85 ± 0.307-1.71 ± 0.298
SecondaryPercentage of Participants Who Achieved Weight Loss of ≥5%

Percentage of Participants who Achieved Weight Loss ≥5% is reported here.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Weight Loss of ≥5%
percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants Who Achieved Weight Loss of ≥5%25.8149.1260.001.72
SecondaryPercentage of Participants Who Achieved Weight Loss of ≥10%

Percentage of Participants who Achieved Weight Loss ≥10% is reported here.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Weight Loss of ≥10%
percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants Who Achieved Weight Loss of ≥10%8.0621.0525.450.00
SecondaryPercentage of Participants Who Achieved Weight Loss of ≥15%

Percentage of Participants who Achieved Weight Loss ≥15% is reported here.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Weight Loss of ≥15%
percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants Who Achieved Weight Loss of ≥15%4.845.269.090.00
SecondaryPercent Change From Baseline in Daily Mean Insulin Glargine Dose

LS Mean was calculated using MMRM for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Baseline HbA1c (\<=8.0%, \>8.0%) + SGLT2i Use (Yes/No) + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Daily Mean Insulin Glargine Dose
percent change5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Percent Change From Baseline in Daily Mean Insulin Glargine Dose23.90 ± 6.42421.95 ± 6.47118.21 ± 6.36469.28 ± 8.826
SecondaryPercentage of Participants With HbA1c <7.0%, Without Weight Gain (<0.1 Kilogram [kg]) and Without Hypoglycemia, (Blood Glucose <3.0 mmol/L <54 Milligram/Deciliter [mg/dL])

Percentage of Participants with HbA1c \<7.0%, Without Weight Gain (\<0.1 Kilogram \[kg\]) and Without Hypoglycemia, (Blood Glucose \<3.0 mmol/L \<54 Milligram/Deciliter \[mg/dL\]) is reported here

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c <7.0%, Without Weight Gain (<0.1 Kilogram [kg]) and Without Hypoglycemia, (Blood Glucose <3.0 mmol/L <54 Milligram/Deciliter [mg/dL])
percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants With HbA1c <7.0%, Without Weight Gain (<0.1 Kilogram [kg]) and Without Hypoglycemia, (Blood Glucose <3.0 mmol/L <54 Milligram/Deciliter [mg/dL])59.6870.1867.275.17
SecondaryPercentage of Participants With HbA1c ≤6.5%, Without Weight Gain <0.1 kg and Without Hypoglycemia (Blood Glucose <3.0 mmol/L [54 mg/dL])

Percentage of Participants with HbA1c ≤6.5%, Without Weight Gain \<0.1 kg and Without Hypoglycemia (Blood glucose \<3.0 mmol/L \[54 mg/dL\]) is reported here.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c ≤6.5%, Without Weight Gain <0.1 kg and Without Hypoglycemia (Blood Glucose <3.0 mmol/L [54 mg/dL])
percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants With HbA1c ≤6.5%, Without Weight Gain <0.1 kg and Without Hypoglycemia (Blood Glucose <3.0 mmol/L [54 mg/dL])46.7770.1861.821.72
SecondaryPercentage of Participants With HbA1c <7.0%, Without Weight Gain <0.1 kg and Without Hypoglycemia (Blood Glucose <3.9 mmol/L [70 mg/dL] or Severe Hypoglycemia)

Percentage of Participants with HbA1c \<7.0%, Without Weight Gain \<0.1 kg and Without Hypoglycemia (Blood Glucose \<3.9 mmol/L \[70 mg/dL\] or Severe Hypoglycemia) is reported here.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c <7.0%, Without Weight Gain <0.1 kg and Without Hypoglycemia (Blood Glucose <3.9 mmol/L [70 mg/dL] or Severe Hypoglycemia)
percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants With HbA1c <7.0%, Without Weight Gain <0.1 kg and Without Hypoglycemia (Blood Glucose <3.9 mmol/L [70 mg/dL] or Severe Hypoglycemia)51.6157.8947.275.17
SecondaryPercentage of Participants With HbA1c ≤6.5%, Without Weight Gain <0.1 kg and Without Hypoglycemia (Blood Glucose <3.9 mmol/L [70 mg/dL] or Severe Hypoglycemia)

Percentage of Participants with HbA1c ≤6.5%, Without Weight Gain \<0.1 kg and Without Hypoglycemia (Blood glucose \<3.9 mmol/L \[70 mg/dL\] or Severe Hypoglycemia) is reported here.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c ≤6.5%, Without Weight Gain <0.1 kg and Without Hypoglycemia (Blood Glucose <3.9 mmol/L [70 mg/dL] or Severe Hypoglycemia)
percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants With HbA1c ≤6.5%, Without Weight Gain <0.1 kg and Without Hypoglycemia (Blood Glucose <3.9 mmol/L [70 mg/dL] or Severe Hypoglycemia)38.7157.8943.641.72

Adverse events

Collected over Baseline up to week 44. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
5 mg Tirzepatide1/65 (1.5%)8/65 (12.3%)45/65 (69.2%)
10 mg Tirzepatide0/65 (0%)5/65 (7.7%)49/65 (75.4%)
15 mg Tirzepatide0/63 (0%)8/63 (12.7%)49/63 (77.8%)
Placebo0/64 (0%)7/64 (10.9%)31/64 (48.4%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
Event5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Ovarian cystReproductive system and breast disorders0/230/251/260/25
CataractEye disorders1/650/651/631/64
Retinal detachmentEye disorders0/650/651/630/64
Gastrointestinal disorderGastrointestinal disorders0/650/651/630/64
Large intestine polypGastrointestinal disorders0/651/651/630/64
MassGeneral disorders0/650/651/630/64
PneumoniaInfections and infestations1/650/651/630/64
Soft tissue infectionInfections and infestations0/650/651/630/64
Limb injuryInjury, poisoning and procedural complications0/650/651/630/64
Upper limb fractureInjury, poisoning and procedural complications0/650/651/630/64
Most frequent other events
Showing 10 of 19
Most frequent other events
Event5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
DiarrhoeaGastrointestinal disorders17/6524/6523/635/64
Decreased appetiteMetabolism and nutrition disorders19/6516/6520/630/64
Lipase increasedInvestigations12/6514/656/632/64
Upper respiratory tract infectionInfections and infestations13/6511/6511/639/64
Amylase increasedInvestigations4/658/653/632/64
NauseaGastrointestinal disorders3/657/657/632/64
Abdominal distensionGastrointestinal disorders7/653/654/630/64
HyperuricaemiaMetabolism and nutrition disorders4/653/656/632/64
VomitingGastrointestinal disorders4/656/654/630/64
HyperlipidaemiaMetabolism and nutrition disorders2/655/653/634/64

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Mean58.10 ± 9.9755.00 ± 11.5855.80 ± 10.1158.00 ± 10.2456.70 ± 10.53
Sex: Female, Male
Sex: Female, Male(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Female2325262599
Male42403739158
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Hispanic or Latino00000
Not Hispanic or Latino65656364257
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
American Indian or Alaska Native00000
Asian65656364257
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
China65656364257
Percentage of Hemoglobin A1c (HbA1c) at Baseline
Percentage of Hemoglobin A1c (HbA1c) at Baseline(Percentage of HbA1c)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Mean8.64 ± 0.958.60 ± 1.098.75 ± 0.998.84 ± 0.998.71 ± 1.01
08

Study locations

25 sites
  • The Second People's Hospital of Hefei
    Hefei, Anhui 230011, China
  • Beijing Hospital
    Beijing, Beijing Municipality 100005, China
  • Beijing Pinggu District Hospital
    Beijing, Beijing Municipality 101200, China
  • Chongqing General Hospital
    Chongqing, Chongqing Municipality 400014, China
  • Huizhou Municipal Central Hospital
    Huizhou, Guangdong 516001, China
  • The First Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • The Fourth Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • The First Affiliated Hospital of Henan University of Science &Technology
    LuoyangShi, Henan 471003, China
  • The Second Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450014, China
  • The First People's Hospital of Yueyang
    Yueyang, Hunan 414000, China
  • Baotou Central Hospital
    Baotou, Inner Mongolia 014040, China
  • Changzhou No.2 People's Hospital
    Changzhou, Jiangsu 213000, China
  • Nanjing First Hospital
    Nanjing, Jiangsu 210006, China
  • Zhongda Hospital Southeast University
    Nanjing, Jiangsu 210009, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210011, China
  • Wuxi People's Hospital
    Wuxi, Jiangsu 214023, China
  • The Affiliated Jiangyin Hospital of Southeast University Medical College
    WuxiShi, Jiangsu 214400, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 212000, China
  • The Third Hospital of Nanchang
    Nanchang, Jiangxi 330009, China
  • The First Affiliated Hospital of Xi'an Medical University
    Xi'an, Shaanxi 710077, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
  • Chengdu Fifth People's Hospital
    Chengdu, Sichuan 611130, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin Municipality 300052, China
  • Huzhou Central Hospital
    Huzhou, Zhejiang 313000, China
09

References and documents

Publications

  • Guo L, Dong X, Ma J, Liu M, Lu Y, Wang H, Li Q, Li L, Deng Y, Xu J. Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2025 Dec;13(12):1015-1029. doi: 10.1016/S2213-8587(25)00248-7. Epub 2025 Oct 27. PubMed 41167231 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: ata are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Jul 2024, 16 months.

Results were first posted in Aug 2025, 1 year 1 month after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 16 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2023
First posted
Jan 20, 2023
StartActual
Feb 5, 2023
Primary completionActual
Jul 1, 2024
CompletionActual
Jul 1, 2024
Results first posted
Aug 8, 2025
Last update
Aug 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05691712
Responsible party
Sponsor
First posted
Jan 20, 2023
Start date
Feb 5, 2023
Primary completion
Jul 1, 2024
Completion
Jul 1, 2024
Results posted
Aug 8, 2025
Last update
Aug 8, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion